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Implication of 5-HT7 receptor in prefrontal circuit assembly
and detrimental emotional effects of SSRIs during
development
Jimmy Olusakin1,2,8, Imane Moutkine1,2, Sylvie Dumas 3, Evgeni Ponimaskin4, Eleni Paizanis5, Mariano Soiza-Reilly 1,2,6 and
Patricia Gaspar 1,2,7
Altered development of prefrontal cortex (PFC) circuits can have long-term consequences on adult emotional behavior. Changes in
serotonin homeostasis during critical periods produced by genetic or pharmacological inactivation of the serotonin transporter
(SERT, or Slc6a4), have been involved in such developmental effects. In mice, selective serotonin reuptake inhibitors (SSRIs),
administered during postnatal development cause exuberant synaptic connectivity of the PFC to brainstem dorsal raphe nucleus
(DRN) circuits, and increase adult risk for developing anxiety and depressive symptoms. SERT is transiently expressed in the
glutamate neurons of the mouse PFC, that project to the DRN. Here, we find that 5-HTR7 is transiently co-expressed with SERT by
PFC neurons, and it plays a key role in the maturation of PFC-to-DRN synaptic circuits during early postnatal life. 5-HTR7-KO mice
show reduced PFC-to-DRN synaptic density (as measured by array-tomography and VGLUT1/synapsin immunocytochemistry).
Conversely, 5-HTR7 over-expression in the developing PFC increased PFC-to-DRN synaptic density. Long-term consequences on
depressive-like and anxiogenic behaviors were observed in adults. 5-HTR7 over-expression in the developing PFC, results in
depressive-like symptoms in adulthood. Importantly, the long-term depressive-like and anxiogenic effects of SSRIs (postnatal
administration of fluoxetine from P2 to P14) were not observed in 5-HTR7-KO mice, and were prevented by co-administration of the
selective inhibitor of 5-HTR7, SB269970. This study identifies a new role 5-HTR7 in the postnatal maturation of prefrontal
descending circuits. Furthermore, it shows that 5-HTR7 in the PFC is crucially required for the detrimental emotional effects caused
by SSRI exposure during early postnatal life.
Neuropsychopharmacology (2020) 0:1–11; https://doi.org/10.1038/s41386-020-0775-z
INTRODUCTION
Enhanced vulnerability to emotional disorders such as anxiety and
depression can result from altered developmental trajectories
during early life [1]. This, in turn, can be related to a combination
of genetic and environmental factors including early-life stress,
malnutrition, or drug exposure. In these conditions, perturbed
serotonin (5-HT) signaling has been implicated as a causal agent
because of its impact on brain development [2–4].
One of the most remarkable and clinically relevant examples of
5-HT’s developmental effects is the exposure of human fetuses or
infants to selective serotonin reuptake inhibitors (SSRIs) [5].
Contrasting with their antidepressant effects in adulthood,
fluoxetine, as other SSRIs, when administered during early life,
have long-term effects on adult emotional behavior including
enhanced anxiety and depressive-like phenotypes [6]. Similarly,
serotonin transporter (SERT) knock-out mice show increased
anxiety and depressive-like behaviors [7, 8], and humans carrying
the hypofunctional s-allele of the SERT gene have increased risk to
mood disorders after early adversity [9, 10]. Overall, these
observations indicated that increased 5-HT signaling obliterates
normal physiological balances during a critical period when the
neural circuits that underlie stress-related behaviors are being
remodeled by activity-dependent processes [11].
The difference in the action of SSRIs in development and adults
could be explained by changes in cellular targets of SSRIs
at different critical periods of life. While SERT is expressed
exclusively in the 5-HT-producing neurons of the raphe nuclei in
adult brain, it has a broader expression during fetal and early
postnatal life in rodents [12, 13] and primates including humans
[[14, 15]; http://www.brainspan.org]. This suggested that SERT has
specific developmental functions, in particular to buffer 5-HT
accumulation and thereby controlling 5-HT receptor (5-HTR)
activation [3, 16]. Recently, a key neuronal circuit involved in
mood control, the descending prefrontal projection to raphe
neurons [17–19] has been found to transiently express SERT,
during the first 2 weeks of life. SERT is expressed in layer 5–6
glutamate projection neurons of the prefrontal cortex (PFC), in
particular those projecting to the dorsal raphe nucleus (DRN).
Genetic ablation or pharmacological blockade of SERT function in
these neurons alters the glutamatergic synapse development [20].
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We reasoned that 5-HTRs expressed simultaneously with SERT in
the PFC, would be likely candidates to mediate these develop-
mental effects. Based on gene expression profiling we identified
the 5-HTR7 as a possible candidate. The 5-HTR7 promotes axon
growth and synaptogenesis in vitro [21–23], suggesting a role in
neural circuit development and structural plasticity [24]. Moreover,
5-HTR7 has been implicated in mood control, based on
pharmacological studies showing that antagonizing 5-HTR7
attenuates anxiety and depression-like phenotypes [25–28].
Furthermore, a variant of 5-HTR7 has been associated to a better
response to SSRIs in bipolar patients [29].
In the present study, we used a combination of genetic,
pharmacological and high-resolution imaging approaches to
evaluate the developmental role of 5-HTR7 in the synaptic wiring
of the PFC-to-DRN circuit and adult emotional behavior. We
provide converging evidence that 5-HTR7 is crucially required for
the detrimental developmental effects of SSRIs on the PFC circuit
assembly, with a direct impact on adult emotional control.
METHODS AND MATERIALS
Animals
Animal care and experiments were conducted in accordance with
the institutional guidelines. All procedures have been approved by
the ethical committee of the region Ile de France (Comité Darwin,
agreement 09047.04). C57BL/6 (Janvier, France) and 5-HTR7
knockout (5-HTR7−/−) mice [26, 30], maintained on a C57BL/6
background, were used. At arrival, pregnant females were group-
housed by 2 and litter sizes were homogenized from 8–14 animals
with both sexes represented. After weaning at P21, all mice were
group-housed by sex (4–5 per cage), and kept under standard
laboratory conditions (22 ± 1 °C, 60% relative humidity, 12–12 h
light–dark cycle, food and water ad libitum) in ventilated racks.
Male and female mice were used, and the number of individuals
used are provided in Figure legends.
Drug administration
Fluoxetine hydrochloride (FLX, Tocris, UK) and SB269970 (Abcam,
#ab120508) were used. FLX was diluted in 3% sucrose when
administered orally, or in saline (0.9% NaCl) when administered
subcutaneously. Subcutaneous injections (1 ml/kg) were carried
out only in experiments where pups received a second treatment
that cannot be orally administered (i.e., SB269970) [31]. SB269970
was administered at 10 mg/kg twice daily based on previous
studies [28].
Mixed litters born from 5-HTR7−/− x 5-HTR7+/− breedings were
given FLX (10 mg/kg/day) or sucrose (3% in water) orally from P2
to P14. Litters were separated from their dam, weighed, and fed
either the FLX/sucrose or sucrose solution with a P10 pipette,
before being returned to their dams. As pups very readily absorb
the sucrose, the entire procedure lasted <5min per litter, and had
no visible consequences on maternal care to pups. Genotyping
was performed at weaning using primers to detect the neo
cassette and the deleted exon 2 gene (Supplementary Table S1).
Litters of C57BL/6 mice were randomly assigned to: Saline
(Control; 0.9% NaCl/24 h); Fluoxetine (FLX; 10 mg/kg/24hs); FLX
(10 mg/kg/24 h) plus SB269970 (10 mg/kg/12 h) (in this condition,
FLX was co-administered with one of the SB269970 injections);
and SB269970 (10 mg/kg/12 h). Drugs and vehicle were adminis-
tered s.c. from P2 to P14.
RT-qPCRs
Brains of mice euthanized at P1, P7, P14, and P60 (n= 5/age) were
extracted and kept on ice while PFCs were dissected out. 2–3
brains were pooled for each age analyzed. Samples were directly
processed for RNA isolation with Trizol reagent (ThermoFisher,
France, #15596026) following standard protocols. Genomic DNA
was cleared using DNaseI (ThermoScientific, France, #EN0521) and
RT-PCR was done with SuperScript II kit (Invitrogen, USA,
#18064014) using ThermoScientific SYBR Green Mix. Primers are
provided in Supplementary Table S1.
In situ hybridization (ISH)
The following probes were used for 5-HTR7 mRNA: NM_008315.3
sequence 602–1372, Slc6a4 mRNA: NM_013034.4 sequence
1192–2047, and GFP: NM_013645 sequence 74–588.
Brains of P0, P7, P14, P21, and adult mice (n= 3–4/age; P0=
birth) were rapidly frozen in isopentane at −30 °C and stored at
−80 °C. Tissue blocks were sectioned at 15 μm on a cryostat, and
dried at −20 °C for at least 60 min.
Colorimetric ISH was carried out as described previously [32],
using a 5-HTR7 DIG-labeled probe, phosphatase-coupled anti-DIG
antibodies (1:1000), and developed with NBT/BCIP. For double
labeling experiments the RNAscope Multiplex Fluorescent Reagent
Kit (Advanced Cell Diagnostics, France) was used. Probes were
designed by Advanced Cell Diagnostics to target: Slc6a4 (#315851)
and 5-HTR7 (#401321-C3). ISH was performed according to the
protocol of the RNAscope Multiplex Fluorescent Reagent Kit v1
(#320851). Before mounting, sections were incubated with DAPI.
ISH imaging was done in a Zeiss Axioscan microscope at 20X,
while FISH images were acquired with a confocal microscope at
20X and 63X.
5-HTR7-EGFP construct
The construction of the 5-HTR7 fused to EGFP has been described
previously [33]. The 5-HTR7-EGFP fusion construct was then
cloned into an AAV plasmid under control of the neuron
specific synapsin promoter [34]. This plasmid was used for
production of the rAAV8 (Vector Core, Univ. North Carolina, USA)
coding for 5-HTR7-EGFP. AAV-9-hSyn-eGFP-WPRE-bGH (Penn
Vector Core, USA) was used as sham. The AAV8-9 serotypes were
chosen based on the rapidity and efficiency of neuronal
transfection [35].
PFC viral injections
Newborn mice were separated from their dams and randomly
assigned to 5-HTR7 overexpression group (rAAV8-Syn(H1-2)-5-
HTR7-EGFP) or sham group (AAV-9-hSyn-EGFP-WPRE-bGH). Titer
ranges were of 1012–1013 particles/ml. P1 pups were cold-
anesthetized and bilaterally injected (50 nl each) using a pulled
glass capillary mounted on a hydraulic micromanipulator as
before [20]. The whole procedure takes about 5–10min per pup.
After surgeries, pups were warmed and rapidly returned to their
home cages with the mothers.
Array tomography
Fixed brain tissue containing the DRN were processed for array
tomography as previously [36, 37]. Tissue was ultrasectioned in
series of 25 100 nm-thick sections in an ultramicrotome (Leica)
[36, 37]. Polyclonal antibodies anti-Tryptophan hydroxylase
(sheep, 1:200; Millipore, USA; AB1541), anti-VGLUT1 (guinea pig,
1:1000; Millipore, USA; AB5905) and anti-Synapsin 1a (rabbit, 1:200;
Cell Signaling Technology, MA, USA; D12G5 XP, #5297S) were used
[37]. Fluorescent-conjugated secondary antisera raised in donkey
(Alexa 488,647 and CY3, 1:100; Jackson ImmunoResearch, USA)
were applied for revelation. Sections were imaged in a Leica
DM6000 fluorescence microscope using a 63X NA 1.4 oil objective.
Serial images were processed and analyzed using Fiji as described
previously [36, 37].
Behavioral studies
Behavioral measurements started at P80 in the following
sequence: (1) Open field (OF), (2) Splash test (ST), (3) Novelty-
suppressed feeding (NSF), (4) Forced-swim test (FST) and 5)
Locomotion. 2-day interval was set between the OF and ST and 7-
day interval between the NSF, FST and locomotor tests to
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minimize interferences. Behaviors were done during the light
cycle (10 a.m.–5 p.m.) as previously [20, 35].
Open field
Mice were allowed to explore brightly lit (400–500 lux) chambers
[50 cm × 50 cm × 45 cm] equipped with an infrared camera (B/W-
CCD with CCTV lens 2.8–12mm) connected to a computer. Mice
were placed in the center of the chamber and allowed to explore
for 9 min. Ambulatory distances, time spent and distance traveled
in the center of the arena were measured with Viewpoint
software.
Splash test
ST was carried out in a fresh cage as before [35], where mice were
individually sprayed on their back twice with 20% sucrose solution
in water and placed in a corner of their home cage. The latency to
start grooming was manually recorded.
Novelty-suppressed feeding
NSF was done in a plastic box [50 × 80 × 20 cm] with the floor
covered with 3 cm of wooden bedding. 24 h before testing, mice
were food deprived in their home cage. Mice were individually
weighed before and after food deprivation to determine % weight
loss. During the test 2 food pellets were placed on a circular white
filter paper (12 cm diameter) located in the center of the arena.
Mice were placed in a corner of the box and latencies to approach
pellets and feed were recorded [20]. After the test, the weight of
pellet consumption in the home cage during 5min was registered.
Forced-swim test
FST was carried out in a glass cylinder (40 cm × 20 cm diameter)
filled half-way with water (23–24 °C). Mice were tested over 2 days
for 6 min each day after which they were dried and returned to
their home cages. All swim sessions were videotaped and time of
immobility during the second day session was quantified [20].
Locomotor activity
Mice were introduced into a circular corridor (4.5 cm width, 17 cm
diameter) equipped with four infrared beams equidistantly
located every 90° (Imetronic, Pessac, France). Locomotor activity
was recorded for 30 min [20].
Statistical analyses
Sample size was established by previous pilot and published studies.
Mice of each genotype/sex were randomly assigned to different
studies. Data distribution was controlled for normality by Q-Q plots,
and when ANOVA was applied the homogeneity of variances of the
data was tested. For array tomography, the results obtained from
two stacks were averaged to generate a mean value per mouse.
Data were analyzed using multifactorial ANOVA or two-tailed
Student’s t-test, using Prism 6 and IBM SPSS 20. Data are expressed
as mean ± SEM. Significance was established at p < 0.05.
RESULTS
5-HTR7 is expressed in PFC-SERT+ neurons during early postnatal
development
The neurons of the PFC that transiently express SERT during early
postnatal mouse development constitute a very specific sub-
population of glutamate projection neurons of layers 5 and 6. To
determine which 5-HTRs are present in PFC-SERT+ neurons, we
analyzed data obtained in a previous RNA sequencing study of
FACS-isolated PFC-SERT+ neurons at P7 [20]. This analysis
indicated that the 5-HTR7 has the highest expression in PFC-
SERT+ neurons, followed by the 5-HTR1F, 5-HTR5A, and 5-HTR1D,
whereas other classical cortical receptor subtypes like the 5-HTR1A
or 5-HTR2A have only a minor expression (Fig. 1a). Real-time
quantitative PCR (qPCR) studies corroborated the coincidence of
5-HTR7 and SERT expression in the PFC at P7 (Fig. 1b).
Furthermore, extended qPCR analysis at different postnatal ages
showed that 5-HTR7 mRNA is already present in the PFC by P1,
that this expression increases by P7 and peaks at P14, with a
moderate reduction by P60 (Fig. 1b). In situ hybridization (ISH)
results revealed layer-specific expression profiles in the PFC,
indicating that 5-HTR7 is abundantly expressed in cortical neurons
of layer 2 and layers 5–6 at P0, P7 and P14 (Fig. 1c,c’;
Supplementary Fig. S1). However, at later ages (P21), the 5-HTR7
mRNA expression decreased substantially in deep layers, while
expression in layer 2 remained moderate (in the mPFC) (Fig. 1d,d’;
Supplementary Fig. S1) to high (in the anterior cingulate cortex)
(Supplementary Fig. S1). To further explore the 5-HTR7 and SERT
co-expression in PFC-SERT+ neurons, we performed double
labeling fluorescent ISH. This study showed robust 5-HTR7 and
SERT co-expression in cortical neurons of layers 5 and 6 at P7
(Fig. 1e, f). We found that 40% of SERT+ neurons in the deep
layers of the mPFC contain 5-HTR7 transcripts, indicating the
presence of a subpopulation of SERT+ neurons expressing the
receptor by P7. In addition, a similar proportion of 5-HTR7-
expressing neurons within the same cortical region contained
SERT transcripts (Fig. 1g). Overall, these observations indicated
that 5-HTR7 is expressed in the mPFC, with a strong transient
expression in deep cortical layers during the first weeks of
postnatal life, and is co-expressed with SERT in these neurons.
5-HTR7 regulates the PFC-to-DRN circuit assembly
Fluoxetine (FLX) exposure during a critical period of postnatal age
(P2–P14) produces an increased number of PFC glutamatergic
synapses onto 5-HT and GABA neurons in the dorsal raphe
nucleus (DRN) [20]. To determine whether 5-HTR7 is involved in
this effect, we examined the consequences of 5-HTR7 loss and
gain of function. The synaptic density of PFC glutamatergic inputs
to the DRN was measured by the high-resolution immunofluor-
escence technique array tomography [38]. This microscopy
technique allows identifying cortical axon terminals containing
the vesicular glutamate transporter type 1 (VGLUT1) [37, 38].
Cortical afferents to the DRN arise mainly from the PFC [39–41].
Because of this, VGLUT1 immunolabelling can be used as a
readout of PFC synaptic afferents, together with the co-labeling of
synapsin 1a, a general marker for synaptic boutons [37, 42]. In
addition, tryptophan hydroxylase (TPH) immunolabeling deter-
mines the presence of morphological contacts of synaptic
boutons to 5-HT neurons [37, 42] (Fig. 2a, b). Array tomography
quantitative analyses of VGLUT1/synapsin double labeled puncta
in 5-HTR7−/− mice (38,900 puncta analyzed) showed a significant
reduction of 18% (t8= 2.680; p < 0.03) compared with littermate
controls (5-HTR7−/+ mice; 29,938 puncta analyzed) (Fig. 2c, d),
suggesting a role in PFC-to-DRN circuit formation of 5-HTR7. The
analysis of VGLUT1/synapsin double labeled boutons onto 5-HT
neurons showed a non-significant trend to decrease, suggesting
that total changes observed (Fig. 2d) would have a preferential
impact on non-5-HT neurons of the DRN (Fig. 2e; a total of 11,025
and 8,553 puncta analyzed for 5-HTR7−/+ and 5-HTR7−/− mice,
respectively).
To further interrogate the role of 5-HTR7 in the development of
PFC neurons we selectively over-expressed the full length 5-HTR7
with the C-terminal fused to GFP under the control of the synapsin
promoter [33]. Previous studies from our group showed that this
promoter preferentially drives AAV transduction in pyramidal
glutamate projection neurons of the mPFC [35]. Bilateral injections
of AAV8-hSyn-5-HTR7-EGFP in the PFC were done at P1 (Fig. 3a).
Histological control showed expression exclusively in the frontal
pole including orbital, prelimbic and infralimbic regions of the
PFC, with a large number of transduced neurons in layer 5–6
neurons at P7 (Fig. 3b). The GFP-labeling was concentrated in the
neuronal membranes, within the somatodendritic compartment
(Fig. 3c,c′), and in dendritic spines (Fig. 3c′′) as well as well as in
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PFC efferent axons. Importantly, in the brainstem, labeling was
noted in axon terminals within the DRN, in close proximity to 5-HT
labeled neurons (Fig. 3d,d′). Next, we corroborated the virally-
induced over-expression levels of the 5-HTR7 mRNA in the PFC by
qPCR at P7. The viral construct over-expressed the 5-HTR7 mRNA
about 25 times above the expression levels of sham controls
(injected with AAV-9-hSyn-EGFP-WPRE-bGH). Further, such
increase in 5-HTR7 expression levels was not longer evidenced
in adulthood (Supplementary Fig. S2). Using these tools, we
observed that 5-HTR7 over-expression in the PFC caused a
significant increase in the density of VGLUT1/synapsin double
labeled puncta in the DRN when compared with sham control
mice (t8= 6.185; p < 0.0003) (a total of 54,922 and 34,267 puncta
analyzed for 5-HTR7-over-expressing and sham mice, respectively)
(Fig. 3e). This effect was also evident when analyzing the double
labeled synaptic puncta in morphological contact with TPH-
positive neurons (t8= 5.895; p < 0.0004) (17,763 and 8735 puncta
analyzed for 5-HTR7-overexpressing and sham mice, respectively)
(Fig. 3f).
Next, we asked whether antagonizing the 5-HTR7 may prevent
the morphological synaptogenic effects of FLX exposure during
the postnatal critical period. Wild-type mouse pups were
administered with FLX or saline, alone or together with the
selective 5-HTR7 antagonist SB269970 [31] daily from P2 to P14
(Fig. 3g). Two-way ANOVA results showed no significant interac-
tion between FLX/SAL treatment and SB269970 treatment (F1,14=
0.890; p= 0.36). Confirming our previous observations, the density
of VGLUT1/synapsin double labeled terminals was increased in the
FLX-treated mice when compared with the saline-treated controls
(Main Effects: F1,14= 16.773; p < 0.001) (Fig. 3h). This difference
was abolished when SB269970 was co-administered with FLX or
SAL (Main Effects: F1,14= 3.934; p= 0.067) (Fig. 3h). Similarly,
associations of VGLUT1+ synaptic boutons with TPH-positive
neurons were also increased by FLX treatment (Main Effects:
F1,14= 8.877; p < 0.01), but these differences disappeared when
administering SB269970 (Main Effects: F1,14= 4.198; p < 0.06)
(Fig. 3i).
Overall, these experiments indicate that 5-HTR7 controls the
formation of efferent PFC projections to the brainstem DRN during
early postnatal life, highlighting the requirement of 5-HTR7 for the
morphogenetic effects of postnatal FLX exposure on the PFC-to-
DRN synaptic circuit.
5-HTR7 engagement in shaping adult emotional behaviors
To assess the developmental role of 5-HTR7 in adult emotional
phenotypes, we generated new cohorts of the different experi-
mental groups described above to examine behavioral effects in
adulthood, focusing on anxiogenic and depressive-like behaviors.
Fig. 1 5-HTR7 expression in the mouse mPFC is developmentally regulated during the early postnatal period. a Relative proportion of 5-
HT receptor genes (Htr) expressed in PFC-SERT+ neurons at P7, as revealed by RNA sequencing profiling of FACS-isolated SERTCre::EGFP
neurons from the mPFC. b Time course of 5-HTR7 and SERT mRNA expression by q-PCR on mPFC tissue dissected at P1, P7, P14 and P60 (n=
3–4 per age). *p < 10−6 for SERT at P7 vs. all ages (F3,7= 314.103; p < 10
−7), and 5-HTR7 at P14 vs. P1–P7 (F3,7= 129.497; p < 10
−5) after ANOVA
followed by Tukey’s test. c, d In situ hybridization of 5-HTR7 in the mPFC at P7 (c,c’) and P21 (d,d’) illustrating a laminar shift in the distribution
of the receptor during the early postnatal period. Abundant expression of 5-HTR7 is present in layers 5–6 at early ages (arrows), however by
P21 this expression remains only in superficial 2–3 layers (arrowheads). e, f RNAscope double fluorescent in situ hybridization in the mPFC at
P7 (e, arrow), showing nuclear (DAPI, blue) co-localization of 5-HTR7 mRNA (red) with SERT mRNA (green) expression (arrowheads). Some of
these mPFC neurons present 5-HTR7 mRNA but not SERT expression (f, arrow). g Quantitative analysis of the percentage of mPFC neurons co-
expressing SERT (green) and 5-HTR7 (red) mRNAs.
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Heterozygous breeding was used to generate cohorts of 5-HTR7 +/+;
5-HTR7+/− and 5-HTR7−/− mice. Adult behavioral testing of these
mice did not reveal genotype effects in any of the tests used:
locomotor activity, exploration of an open arena (OF), latency to
groom in the splash test (ST), latency to feed in the novelty
suppressed feeding (NSF), and immobility time in the forced
swim test (FST) (Supplementary Fig. S3). These observations
confirmed the lack of an anxiety phenotype of the 5-HTR7−/−
mice, but did not reproduce the reduced immobility time in the
FST observed in previous studies [26, 43]. Next, we asked whether
the 5-HTR7 could have a role in the adult emotional alterations
induced by postnatal exposure to FLX. To this end, 5-HTR7−/−
and 5-HTR7+/− mice were administered with FLX or vehicle from
P2 to P14 (Fig. 4a). Two-way ANOVA results showed no
interaction between genotype and treatment factors in the total
distance traveled in the OF (F1,72= 2.656; p= 0.108) (Fig. 4b). In
contrast, FLX-treated mice showed decreased exploration of the
arena (Main Effects: F1,72= 17.606; p < 0.0001), with a robust
genotype effect (Main Effects: F1,72= 7.406; p < 0.008) (Fig. 4b).
The results of time spent in the center of the OF arena showed a
significant genotype x treatment interaction (F1,72= 3.978; p < 0.05).
Simple effects indicated a reduction in the time exploring the center
of the arena only in FLX-treated 5-HTR7+/− mice in comparison to
control treated littermates (F1,28= 10.954; p < 0.003). (Fig. 4c). No
differences between treatments or genotypes were observed in
total distance traveled in the center (Supplementary Fig. S4a).
Analysis of latency to groom in the ST showed a non-significant
factor interaction (F1,72= 0.002; p= 0.96). However, FLX treatment
increased the latency to groom (Main Effects: F1,72= 22.385;
p < 0.0001) (Fig. 4d), and these differences appeared more
pronouncedly in 5-HTR7+/− mice, however this effect did not reach
significance (Main Effects: F1,72= 0.053; p= 0.82). Similarly, in the
NSF, we did not find a significant factor interaction (F1,72= 2.777;
p= 0.10). In contrast, FLX-treated mice showed an increased latency
to feed (Main Effects: F1,72= 13.619; p < 0.0004) (Fig. 4e), and this
effect was more robust in 5-HTR7+/− mice, although not significant
(Main Effects: F1,72= 3.596; p= 0.06). On the other hand, we did
not find changes in the percentage of weight loss or food
consumption in the home cage among experimental groups
(Supplementary Fig. S4b,c). Evaluation of the floating time in
the FST also showed a non-significant interaction (F1,72= 2.540;
p= 0.12). In this case, FLX-treated mice showed an increase in the
floating time (Main Effects: F1,72= 13.209; p < 0.001) that was more
evident in 5-HTR7+/− mice (Fig. 4f), although did not reach statistical
significance (Main Effects: F1,72= 1.035; p= 0.31). Locomotor activity
in a circular path was not affected either by the treatment or
genotype (Interaction: F1,72= 0.023; p= 0.88; Main Effects treat-
ment: F1,72= 0.451; p= 0.50; Main Effects genotype: F1,72= 2.414;
p= 0.13) (Fig. 4g).
Because experiments in 5-HTR7−/− mice do not allow assessing
the tissue-specific spatiotemporal requirement of 5-HTR7 expres-
sion, we used the viral over-expression approach described
previously to specifically interrogate the developmental role of
PFC 5-HTR7 in shaping adult emotional behaviors. We compared
adult mice that had been injected at P1 with the viral construct
encoding for 5-HTR7-GFP, with those injected with the viral
construct encoding only for the GFP reporter (Fig. 4h). Behavioral
analysis of these mice revealed a reduced exploration and time
spent in the center of the arena in the OF (t26= 6.222; p < 0.0001
and t26= 3.638; p < 0.002, respectively) (Fig. 4i, j), without changes
in distances traveled in the center (Supplementary Fig. S4d). In
addition, increased latency to groom in the ST (t26= 6.145; p <
0.0001) (Fig. 4k) and to feed in the NSF (t26= 3.082; p < 0.005)
(Fig. 4l) were also observed. In the NSF, no differences in body
weight before and after the testing session, or in home cage pellet
consumption, were registered (Supplementary Fig. S4e,f). In the
FST, increases in floating times were found (t26= 4.411; p < 0.0002)
(Fig. 4m). In contrast, no changes in locomotor activity were noted
among experimental groups (t26= 0.480; p= 0.64) (Fig. 4n).
Altogether, our results uncover a crucial role of 5-HTR7 in the
developmental effects of FLX on adult anxiety and depressive-like
behavior. Moreover, our findings indicate that the transient
presence of 5-HTR7 in the PFC during early postnatal life is
sufficient to largely replicate emotional alterations induced by FLX
at this time period.
Developmental 5-HTR7 blockade prevents detrimental paradoxical
effects of SSRIs on emotional behavior
Next, we evaluated the potential benefit of antagonizing the 5-
HTR7 during the postnatal FLX treatment to prevent the
detrimental long-term effects on emotional behaviors. For this
purpose, the specific 5-HTR7 antagonist SB269970 was co-
administered with FLX during the critical period (from P2 to
P14) in wild-type mice and emotional behaviors were investigated
in adulthood (Fig. 5a). Two-way ANOVA results of the total
distance traveled in the OF showed a non-significant interaction
between FLX/SAL and SB269970 treatments (F1,52= 1.463; p=
0.232). Consistent with previous studies, FLX treatment decreased
Fig. 2 Genetic ablation of the 5-HTR7 diminishes the synaptic
afferents of the PFC-to-DRN circuit. a Diagram indicates the region
sampled for the array tomography quantitative analysis. b Array
tomographic render from seven 100 nm thick sections immunola-
beled for tryptophan hydroxylase (TPH, green), synapsin (red) and
the vesicular glutamate transporter type (VGLUT1, blue). The
zoomed-in area in the right panel shows four serial sections in
which VGLUT1 and synapsin co-label the same axon bouton
(arrowhead), in close apposition to TPH+ neuronal profiles.
c Representative high-resolution array tomography image of double
labeled puncta against VGLUT1 and synapsin (arrows) in a 100 nm
thick section of the DRN from 5-HTR7+/− and 5-HTR7−/− mice.
Quantitative analysis of PFC glutamatergic synaptic afferents in the
DRN of 5-HTR7+/− and 5-HTR7−/− mice. All VGLUT1/synapsin+
puncta (t8= 2.680; p < 0.03) (d), and VGLUT1/synapsin+ puncta in
contact with TPH+ neurons (t8= 1.348; p= 0.22) (e) are shown.
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the exploration in the OF in comparison to saline-treated mice
(Main Effects: F1,52= 23.289; p < 0.0001) (Fig. 5b), and this effect
was not evident after SB269970 co-administration (Main Effects:
F1,52= 0.808; p= 0.37) (Fig. 5b). Time spent in the center of the
arena showed an apparent interaction between treatments that
did not reach significance (F1,52= 3.985; p= 0.0512). Consistent to
what happened with total distance traveled, FLX treatment
decreased the time spent in the center (Main Effects: F1,52=
7.708; p < 0.008), and this reduction was not longer visible
when SB269970 was co-administered (Main Effects: F1,52= 1.235;
Fig. 3 Developmental role of 5-HTR7 in the synaptic wiring of the PFC-to-DRN circuit. a, b Bilateral injections of the AAV-hSyn-5-HTR7-EGFP
or AAV-hSyn-EGFP were carried out in the PFC of C57BL/6 mice at P1. Coronal section through the PFC at P12 shows heavy 5-HTR7-GFP
expression in deep cortical layers (b). c High power confocal images of pyramidal neurons expressing the construct encoding 5-HTR7-GFP
(green) with NeuN counterstaining (red). The 5-HTR7-GFP localizes at the cell membrane of pyramidal cell somas (c′) and dendritic
processes including spines (c′′). 5-HTR7-GFP labeling is visible in axon terminals in the DRN (green) (d), often associated with TPH+ neurons
(5-HT, magenta) (d′). Quantification of VGLUT1/synapsin+ axonal boutons in the DRN of P28 mice that received injections of either sham (GFP;
n= 5) or 5-HTR7-EGFP (n= 5) viral constructs in the PFC at P1. All VGLUT1/synapsin+ puncta (e), and VGLUT1/synapsin+ puncta in
contact with TPH+ neurons (f) are shown. *p < 0.001. g–i Four groups of C57BL/6 mice were administered subcutaneously with saline (n= 3),
FLX (10mg/kg/day; n= 5), FLX (10mg/kg/day) + SB269970 (10 mg/kg/12 h) (n= 5) or SB269970 (10mg/kg/12 h; n= 5) during the critical
period (P2–P14) . Array tomography quantitative analyses were carried out in the DRN at P28 in all four experimental groups (g). Density of
VGLUT1/synapsin+ puncta (h) [total number of puncta analyzed for saline (21,510), FLX (45,166), FLX+ SB269970 (35,215) and SB269970 alone
(26,892)], and VGLUT1/synapsin+ puncta related to TPH+ neurons (i) [total number of puncta analyzed for saline (7059), FLX (20,011), FLX+
SB269970 (14,563) and SB269970 alone (8907)]. *p < 0.001 and p < 0.01 for h and i, respectively, FLX vs. all treatments.
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p= 0.27) (Fig. 5c). Total distance traveled in the center was not
changed among all the experimental groups (Supplementary
Fig. S4g).
In the ST, there was a significant interaction between both
treatment factors (F1,52= 20.406; p < 0.0001). Simple effects
showed that the increased latency to groom produced by FLX
when compared with control mice (F1,24= 29.856; p < 0.0001) was
completely prevented by concomitant treatment with SB269970
(F1,25= 11.982; p < 0.002) (Fig. 5d). Interestingly, a less marked but
significant increase in the latency to groom was observed in mice
that had SB269970 alone (F1,27= 8.401; p < 0.007) (Fig. 5d).
In the NSF we found a significant factor interaction in the
latency to feed (F1,51= 9.518; p < 0.003). Simple effect analyses
showed that FLX increase in the latency to feed respect to saline
controls (F1,23= 15.845; p < 0.001), was prevented by SB269970
co-administration (F1,25= 17.082; p < 0.0004) (Fig. 5e). On the
Fig. 4 Engagement of 5-HTR7 in shaping adult emotional behaviors. a 5-HTR7+/− and 5-HTR7−/− mice were treated orally with FLX
(10mg/kg/day in 3% sucrose solution; n= 16 and n= 22 for 5-HTR7+/− and 5-HTR7−/− mice, respectively) or vehicle (3% sucrose solution;
n= 14 and n= 24 for 5-HTR7+/− and 5-HTR7−/− mice, respectively) during the critical period (P2–P14), to evaluate emotional behaviors in the
adulthood (from P80). b Total distance traveled in the Open Field test (OF) (Main Effects treatment: F1,72= 17.606; p < 0.0001), and time spent
in the center of the arena (c) (Interaction treatment x genotype: F1,72= 3.978; p < 0.05 in 5-HTR7
+/− mice, FLX vs. control: F1,28= 10.954;
p < 0.003). d Latency to groom in the Splash Test (ST) (Main Effects treatment: F1,72= 22.385; p < 0.0001). e The latency to feed in the Novelty
Suppressed Feeding Test (NSF) (Main Effects treatment: F1,72= 13.619; p < 0.0004). f Immobility time in the Forced Swim Test (FST) (Main
Effects treatment: F1,72= 13.209; p < 0.001). g Locomotor activity in a circular path (Main Effects treatment: F1,72= 0.451; p= 0.50). h C57BL/6
mice were bilaterally injected with AAV-hSyn-5-HTR7-EGFP (OE; n= 14) or AAV-hSyn-EGFP (Sham; n= 14) in the PFC at P1. Behavioral
measurements were carried out in these mice in the OF (i, j), ST (k), NSF (l) and FST (m), and locomotor activity (n), starting at P80. **p < 0.005
and ****p < 0.0001 in i–n.
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other hand, no differences in body weight or in home cage pellet
consumption were registered (Supplementary Fig. S4h, i).
Two-way ANOVA of the FST data showed a significant factor
interaction (F1,52= 26.952; p < 0.0001). Simple effect ANOVAs
showed that increased floating time produced by FLX exposure
respect to saline controls (F1,24= 18.646; p < 0.0002) was pre-
vented by SB269970 co-administration (F1,25= 17.668; p < 0.0003)
(Fig. 5f). In addition, similarly to what happened in the ST, an
increased immobility time was observed in saline controls after
SB269970 developmental treatment (F1,27= 9.716; p < 0.004),
suggesting a direct selective impact on depressive-like pheno-
types (Fig. 5f). No treatment effects were detected in locomotor
activity among all groups (Fig. 5g).
These results indicate a critical developmental role of 5-HTR7 in
mediating the susceptibility to early postnatal FLX during the
critical period. Furthermore, our findings demonstrate that
concomitant systemic pharmacological antagonism of 5-HTR7 is
sufficient to prevent the appearance of detrimental emotional
effects caused by FLX in the early life.
DISCUSSION
This study identifies 5-HTR7 as a major player in prefrontal circuit
development during the early postnatal period, with impact on
adult emotional behaviors. We demonstrate that both morpholo-
gical and behavioral consequences of a developmental exposure
to SSRIs are dependent on the activation of the 5-HTR7 in the PFC.
Importantly, the depressive-like and anxiety phenotypes caused
by developmental FLX exposure can be prevented by the co-
administration of a selective 5-HTR7 antagonist, opening interest-
ing leads for modulation of antidepressant drug therapies during
child-bearing ages.
In a previous study we identified the transient SERT expression
in PFC neurons as an important target for developmental long-
term detrimental effects of SSRIs [20]. Here, we found that 5-HTR7
is the 5-HT receptor with the highest expression in those cortical
SERT+ neurons during early postnatal development. The transient
expression of SERT and 5-HTR7 in the same neurons suggested
the existence of a tight temporal control of 5-HT signaling through
this receptor during this period. That is, the high affinity uptake of
5-HT mediated by SERT is expected to decrease 5-HT availability
for 5-HTR7 at the neuronal cell membrane. Previous localization
studies indicated a fairly broad distribution of 5-HTR7 in the adult
brain including the cerebral cortex [44], but developmental
studies are limited to only few brain regions in the rat [21, 45].
Our study showed that 5-HTR7 in the PFC has a transient
expression in pyramidal neurons of layers 5–6 during the first
3 weeks of life, including SERT+ and SERT- neurons, while the
expression in upper cortical layers is stable until adulthood.
Consistent with our findings, Béïque et al. (2004) showed a
dramatic shift in the effects of 5-HT on membrane potential over
mPFC postnatal development. Specifically, during the first three
postnatal weeks 5-HT induces a rapid depolarization of layer 5
pyramidal cells that can be largely blocked by 5-HTR7 antagonists
but not by 5-HTR2A antagonists. Later in development, the
characteristic 5-HTR1A-mediated adult hyperpolarization of the
same pyramidal neurons produced by 5-HT can be only achieved
after the third postnatal week [46, 47]. This shift in the
physiological responses could be interpreted as a consequence
of 5-HTR7 and 5-HTR1A dimerization, favoring the inhibitory
component of the dimer [48, 49]. However, our data show that the
5-HTR7 expression in deep layer cortical neurons is down-
regulated by P21, consistent with electrophysiology studies
[46, 47].
Transient expression of 5-HTR7 in the PFC coincides with a
period of high developmental plasticity. Pyramidal neurons of
layers 5–6 in the mPFC send subcortical projections to a number
of targets including the basal ganglia, amygdala, hypothalamus,
and brainstem [40, 50]. Most of these projections are still
undergoing active growth and synaptogenesis in subcortical
Fig. 5 Developmental 5-HTR7 blockade prevents detrimental paradoxical effects of SSRIs on emotional behavior. a Four groups of C57BL/
6 mice were administered subcutaneously with saline (n= 14), FLX (10mg/kg/day; n= 12), FLX (10mg/kg/day) + SB269970 (10mg/kg/12 h) (n=
15), or SB269970 alone (10mg/kg/12 h; n= 15) during the critical period (P2–P14) to evaluate adult emotional behaviors (from P80). Total distance
traveled in the OF (b) (Main Effects SAL/FLX treatment: F1,52= 23.289; p < 0.0001), and time spent in the center of the arena (c) (Main Effects SAL/
FLX treatment: F1,52= 7.708; p < 0.008). Latency to groom in the ST (d) (FLX/SAL x SB269970 treatment interaction: F1,52= 20.406; p < 0.0001),
latency to feed in the NSF (e) (FLX/SAL x SB269970 treatment interaction: F1,51= 9.518; p < 0.003), and immobility time in the FST (f) (FLX/SAL x
SB269970 treatment interaction: F1,52= 26.952; p < 0.0001). Locomotor activity (g). **p < 0.01, ***p < 0.002, and ****p < 0.0001.
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targets during the first weeks of postnatal life. In particular,
brainstem-projecting PFC neurons increase their inputs to the DRN
establishing supernumerary excitatory synapses onto 5-HT and
GABA neurons up to P21 [20]. The present experiments indicate
that 5-HTR7 is an important player to modulate this synaptogen-
esis, since over-expression in the PFC increased the number of
glutamatergic synapses in the DRN, while 5-HTR7−/− mice had a
reduced synaptic density. However, the chronic developmental
application of the 5-HTR7 antagonist SB269970 alone did not
modify the number of PFC glutamate synaptic afferents to the
DRN. A possible interpretation of this difference is that in our
pharmacological experiments the 5-HTR7 is only partially blocked
to the actions of 5-HT, especially when considering the narrow
window of action of the SB269970 [31]. However, this partial
action appeared sufficient to counterbalance the overgrowth of
cortical glutamatergic synapses in the DRN produced by devel-
opmental exposure to FLX. It should be noted that estimates of
glutamatergic synapses measured with array tomography could
be affected by decreases in VGLUT1/synapsin expression levels.
However, previous studies indicate a highly consistent electro-
physiological functional correlate of the morphological synaptic
measurements including those produced by developmental
exposure to FLX [20, 37, 51].
5-HT is well known to have multiple morphogenetic roles,
which differ according to 5-HT receptors and cell types [3, 52, 53].
Several in vitro studies concur to show that 5-HTR7 activation has
a trophic effect, as 5-HTR7 agonists increased axon growth and
synaptogenesis in hippocampal and striatal primary cultures
[21, 23, 53]. The present study provides the first demonstration
of an in vivo physiological effect of 5-HTR7 on a well-defined
neural circuit. Compared with previous studies that focused on
dendritic spine formation, we reveal here an additional morpho-
genetic effect on axon terminals, since manipulating 5-HTR7
expression in the PFC was sufficient to cause exuberance of
glutamate terminals in the DRN. Moreover, the localization of 5-
HTR7-GFP fusion protein at PFC axon terminals, strongly argues for
a direct effect of 5-HTR7 stimulation at presynaptic sites, in
addition to its previously identified postsynaptic effects on
dendritic spine formation [21]. It will be interesting in the future
to identify the downstream signaling mechanisms of this
presynaptic effect, as 5-HTR7 is known to activate both Gs-
cAMP-PKA and Gα12-RhoGAP-CDC42 pathways [21, 23, 53]. Our
RNA profiling indicates that players of both pathways are present
in the PFC-SERT+ neurons at P7 [20]. On a translational note, the
demonstration that 5-HTR7 controls synaptogenesis and neural
circuit development in the PFC, offers some interesting mechan-
istic insights to the proposal of 5-HTR7 gene variants as risk factors
in neurodevelopmental psychiatric disorders such as schizophre-
nia [54] and autism spectrum disorders [55].
Exposure to a variety of SSRIs including FLX during the
postnatal period has been repeatedly found to cause anxiety
and depressive-like phenotypes later in life [20, 56–58]. Similarly,
genetic models interfering with SERT function such as SERT-KO
rodents display paradoxical depressive-like behaviors that can be
explained by an increased 5-HT signaling during the first postnatal
weeks [8, 59]. Pharmacological approaches indicated a partial role
of the excess of activation of the 5-HTR1A [8] and 5-HTR2A
receptors [58] in these effects. The present study provides
complementary evidence pointing to a primordial role of the 5-
HTR7 in the long-term emotional detrimental effects of develop-
mental exposure to SSRIs. Depressive-like symptoms and anxio-
genic responses were largely prevented by concomitant
pharmacological treatment with a selective 5-HTR7 antagonist,
and were substantially reduced in 5-HTR7−/− mice receiving
postnatal FLX. Interestingly, developmental blockade of 5-HTR7 by
SB269970 per se produced adult depressive-like behavior but not
anxiety phenotypes, in agreement with previous work showing a
developmental effect of other 5-HT receptors like the 5-HTR2A/C
in anxiety phenotypes [58]. It will be interesting to determine
whether other behavioral symptoms that are due to develop-
mental increases of 5-HT, such as sleep disturbances (increase in
REM sleep) [8, 57] are also dependent on developmental effects of
5-HTR7, as this receptor is strongly expressed in the suprachias-
matic nucleus [44] and involved in the control of circadian
rhythms and sleep [28, 60].
Present experiments showed that over-expression of the 5-
HTR7 in PFC neurons was sufficient to induce anxiety and
depressive-like symptoms in adulthood. Thus, developmental
changes in PFC circuits are likely involved in their occurrence.
However, it is difficult at present to pinpoint the relationship
between specific circuit changes and emotional phenotypes. The
PFC-to-DRN circuit that we focused on is an interesting candidate
as it is recruited in stress control mechanisms and its general
action appears to be that of dampening of 5-HT neuronal activity
[17, 61–63]. Accordingly, stimulation of this pathway has been
shown to have antidepressant effects [19], including in the
postnatal FLX model [20]. Moreover, it is thought to underlie the
beneficial effects of deep brain stimulation in treatment-resistant
depressive patients [64]. Based on these studies, the synaptic
exuberance of PFC terminals in the DRN can be interpreted as
counteracting maladaptive circuit changes in other circuits. In this
interpretation it should be noted that the PFC acts as a hub to
control emotional behaviors by acting on a large number of brain
targets with different outcomes according to targets. For instance
top-down influence of the PFC on the midbrain dopaminergic
neurons was proposed to cause anhedonia [65].
5-HTR7 antagonists have been proposed as a therapeutic
approach in mood disorders [66] and could be an interesting
alternative to SSRIs or combined to sub-threshold doses of SSRIs
for the treatment of depression during pregnancy or postpartum.
Treatment of severe depression in pregnant women remains a
conundrum, because of the known risk to depressive mothers but
also given the possible consequences of antidepressant treat-
ments on child neurodevelopment [5, 67]. Current selective 5-
HTR7 antagonists have a low bioavailability (because of a short
half life and the requirement of parenteral administration) [31].
Interestingly, atypical neuroleptics such as Amisulpride [68] or
Lurasidone [69], that have a high affinity for the 5-HTR7 acting as
inverse agonists, were noted to have antidepressant effects.
However, it remains to be determined whether these compounds
would also be efficient mitigating the developmental detrimental
consequences of SSRIs, as found here for SB269970.
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